Clinical Trials
47 trialsA Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
M.D. Anderson Cancer Center
TALES
University of California, San Francisco
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Fudan University
FASCINATE-N
Fudan University
CAMERAN
UNC Lineberger Comprehensive Cancer Center
SELECT
Yale University
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
PLUM
University of California, San Francisco
POWER II
University of Virginia
I-SPY
QuantumLeap Healthcare Collaborative
ALEPRO
Universitaire Ziekenhuizen KU Leuven
DEBRA
NRG Oncology
CHAMELEON
Memorial Sloan Kettering Cancer Center
Study of Letrozole in Recurrent Gliomas
University of Cincinnati
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
RaPhLRR
Hoosier Cancer Research Network
LaPemERLA
National Cancer Centre, Singapore
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Hebei Medical University Fourth Hospital
EndoMAP
Alliance Foundation Trials, LLC.
FEMUS
Fudan University
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
BFR-ESS
Centre Leon Berard
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
The Affiliated Hospital of Qingdao University
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Weill Medical College of Cornell University
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism
Al-Azhar University
ARIADNE
Karolinska University Hospital
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Fudan University
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Fudan University
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
National University Hospital, Singapore
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
Emory University
ICRG0201
International Cancer Research Group, United Arab Emirates
LEPRE
Ente Ospedaliero Ospedali Galliera
TRAK-ER
Royal Marsden NHS Foundation Trust
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
Second Affiliated Hospital of Soochow University
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
ORACLE-RIPA
National Taiwan University Hospital
Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Shengjing Hospital